Optos focuses on retinal diagnostics with OPKO Instrumentation purchase
This article was originally published in Clinica
Retinal imaging specialist Optos has broadened its footprint in the ophthalmic diagnostics market by agreeing to buy OPKO Health’s instrumentation division for $17.5m. Optos will also make royalty payments to OPKO, depending on future revenues, at a rate of 2.5% or 5%. Royalties payable will not exceed $22.5m in aggregate, suggesting accumulated sales of at least $450m, according to Nomura Code analyst Gary Waanders.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.